ASAnna Schurich

Anna Schurich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Schurich has a total of 275 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-cell assessment of iron content in primary human T cells using laser ablation inductively coupled plasma mass spectrometry

    by Diana M. Carp, Piotr Golda, Alexander Griffiths, Katie Flaherty, Alexander Morrell, Anna Schurich

  • Open Access

    T-cell metabolic ageing as a factor for therapeutic research

    by Ellen King, Bahar Zinali Sohanaki, Anna Schurich

    Ageing is an important determinant of immune function across the lifespan, yet it remains underappreciated in the design and interpretation of much basic T-cell research. As the immune system ages, T-cell responses become less diverse, less efficient, and less adaptable, with consequences for infection control, vaccine responsiveness, cancer immunosurveillance, and the performance of T-cell-based immunotherapies. This issue is particularly acute because many fundamental studies still rely on T cells from, mostly, healthy young donors. These controls are indispensable, but the field has built much of its pre-clinical logic on immune systems that are younger, fitter, and biologically distinct from the patients for whom T-cell therapies are intended. We argue that this mismatch between experimental systems and clinical reality could be overcome by considering age as a routine variable from the start.

  • Open Access

    CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients

    by Molly S. Cook, Ellen King, Katie R. Flaherty, Khadiza Siddika, Sophie Papa, Reuben Benjamin, Anna Schurich


  • Open Access

    A balanced CAR-T cell metabolism driven by CD28 or 4-1BB co-stimulation correlates with clinical success in lymphoma patients

    by Molly S. Cook, Katie R. Flaherty, Sophie Papa, Reuben Benjamin, Anna Schurich

    Chimeric antigen receptor (CAR) T cell therapy has led to unprecedented success in treating relapsed/refractory diffuse large B cell lymphoma (DLBCL). The most common CAR-T cell products currently in the clinic for DLBCL differ in their co-stimulation moiety, containing either CD28 or 4-1BB, which initiate distinct signalling pathways. Previous work has highlighted the importance of T cell metabolism in fuelling anti-cancer function. We have studied the metabolic characteristics induced by CD28 versus 4-1BB co-stimulation in patient CAR-T cells ex vivo . Our data show that in patients, CD28 and 4-1BB drive significantly divergent metabolic profiles. CD28 signalling endows T cells with a preferentially glycolytic metabolism supporting an effector phenotype and increased expansion capacity, while 4-1BB co-stimulation preserves mitochondrial fitness and results in memory-like differentiation. Despite this divergent programming, T cells in patients responding successfully to therapy were metabolically similar, irrespective of co-stimulator, suggesting that efficient fuelling of CAR-T cells in lymphoma requires a ‘ balanced’ metabolism. In contrast, CAR-T cells in non-responders were pushed to their metabolic extremes. One sentence summary: CD28 and 4-1BB signalling drive divergent metabolic profiles in patient CAR-T cells, however patients that respond to therapy have CAR-T cells that maintain metabolic balance.


  • Open Access

    IL-15 reprogramming compensates for NK cell mitochondrial dysfunction in HIV-1 infection

    by Elia Moreno-Cubero, Aljawharah Alrubayyi, Stefan Balint, Ane Ogbe, Upkar S. Gill, Rebecca Matthews, Sabine Kinloch, Fiona Burns, Sarah L. Rowland-Jones, Persephone Borrow, et al.

    Dynamic regulation of cellular metabolism is important for maintaining homeostasis and can directly influence immune cell function and differentiation, including NK cell responses. Persistent HIV-1 infection leads to a state of chronic immune activation, NK cell subset redistribution, and progressive NK cell dysregulation. In this study, we examined the metabolic processes that characterize NK cell subsets in HIV-1 infection, including adaptive NK cell subpopulations expressing the activating receptor NKG2C, which expand during chronic infection. These adaptive NK cells exhibit an enhanced metabolic profile in HIV-1 – individuals infected with human cytomegalovirus (HCMV). However, the bioenergetic advantage of adaptive CD57 + NKG2C + NK cells is diminished during chronic HIV-1 infection, where NK cells uniformly display reduced oxidative phosphorylation (OXPHOS). Defective OXPHOS was accompanied by increased mitochondrial depolarization, structural alterations, and increased DRP-1 levels promoting fission, suggesting that mitochondrial defects are restricting the metabolic plasticity of NK cell subsets in HIV-1 infection. The metabolic requirement for the NK cell response to receptor stimulation was alleviated upon IL-15 pretreatment, which enhanced mammalian target of rapamycin complex 1 (mTORC1) activity. IL-15 priming enhanced NK cell functionality to anti-CD16 stimulation in HIV-1 infection, representing an effective strategy for pharmacologically boosting NK cell responses.


  • Open Access

    Extracellular vesicles in COVID-19 convalescence can regulate T cell metabolism and function

    by Molly S. George, Jenifer Sanchez, Christina Rollings, David Fear, Peter Irving, Linda V. Sinclair, Anna Schurich


  • Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS

    by Laura J. Pallett, Leo Swadling, Mariana Diniz, Alexander A. Maini, Marius Schwabenland, Adrià Dalmau Gasull, Jessica Davies, Stephanie Kucykowicz, Jessica K. Skelton, Niclas Thomas, et al.

    The liver is bathed in bacterial products, including lipopolysaccharide transported from the intestinal portal vasculature, but maintains a state of tolerance that is exploited by persistent pathogens and tumours1,2,3,4. The cellular basis mediating this tolerance, yet allowing a switch to immunity or immunopathology, needs to be better understood for successful immunotherapy of liver diseases. Here we show that a variable proportion of CD8+ T cells compartmentalized in the human liver co-stain for CD14 and other prototypic myeloid membrane proteins and are enriched in close proximity to CD14high myeloid cells in hepatic zone 2. CD14+CD8+ T cells preferentially accumulate within the donor pool in liver allografts, among hepatic virus-specific and tumour-infiltrating responses, and in cirrhotic ascites. CD14+CD8+ T cells exhibit increased turnover, activation and constitutive immunomodulatory features with high homeostatic IL-10 and IL-2 production ex vivo, and enhanced antiviral/anti-tumour effector function after TCR engagement. This CD14+CD8+ T cell profile can be recapitulated by the acquisition of membrane proteins—including the lipopolysaccharide receptor complex—from mononuclear phagocytes, resulting in augmented tumour killing by TCR-redirected T cells in vitro. CD14+CD8+ T cells express integrins and chemokine receptors that favour interactions with the local stroma, which can promote their induction through CXCL12. Lipopolysaccharide can also increase the frequency of CD14+CD8+ T cells in vitro and in vivo, and skew their function towards the production of chemotactic and regenerative cytokines. Thus, bacterial products in the gut–liver axis and tissue stromal factors can tune liver immunity by driving myeloid instruction of CD8+ T cells with immunomodulatory ability.


  • NK cells limit therapeutic vaccine–induced CD8 + T cell immunity in a PD-L1–dependent manner

    by Mariana O. Diniz, Anna Schurich, Senthil K. Chinnakannan, Marion Duriez, Kerstin A. Stegmann, Jessica Davies, Stephanie Kucykowicz, Kornelija Suveizdyte, Oliver E. Amin, Frances Alcock, et al.

    A better understanding of mechanisms that regulate CD8 + T cell responses to therapeutic vaccines is needed to develop approaches to enhance vaccine efficacy for chronic viral infections and cancers. We show here that NK cell depletion enhanced antigen-specific T cell responses to chimp adenoviral vector (ChAdOx) vaccination in a mouse model of chronic HBV infection (CHB). Probing the mechanism underlying this negative regulation, we observed that CHB drove parallel up-regulation of programmed cell death ligand 1 (PD-L1) on liver-resident NK cells and programmed cell death 1 (PD-1) on intrahepatic T cells. PD-L1–expressing liver-resident NK cells suppressed PD-1 hi CD8 + T cells enriched within the HBV-specific response to therapeutic vaccination. Cytokine activation of NK cells also induced PD-L1, and combining cytokine activation with PD-L1 blockade resulted in conversion of NK cells into efficient helpers that boosted HBV-specific CD8 + T cell responses to therapeutic vaccination in mice and to chronic infection in humans. Our findings delineate an immunotherapeutic combination that can boost the response to therapeutic vaccination in CHB and highlight the broader importance of PD-L1–dependent regulation of T cells by cytokine-activated NK cells.


  • Open Access

    Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors

    by Tamara Muliaditan, Leena Halim, Lynsey M. Whilding, Benjamin Draper, Daniela Y. Achkova, Fahima Kausar, Maya Glover, Natasha Bechman, Appitha Arulappu, Jenifer Sanchez, et al.